Is Dasatinib/Startaxed a chemotherapy drug?

Dasatinib (Dasatinib) is an oral targeted drug, a tyrosine kinase inhibitor (TKI), mainly used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Compared with traditional chemotherapy drugs, dasatinib has significant differences in its mechanism of action and toxicity profile, so it cannot be simply classified as a chemotherapy drug.

Traditional chemotherapy drugs achieve anti-cancer effects by killing rapidly dividing cells. This method is less selective for tumor cells and also affects normal rapidly proliferating cells, such as bone marrow, digestive tract and hair follicle cells, leading to extensive toxic reactions such as hair loss, nausea, and bone marrow suppression. In contrast, dasatinib blocks leukemia cell proliferation signals by specifically inhibiting BCR-ABL tyrosine kinase activity, causing malignant cells to stop dividing or apoptosis, while its impact on normal cells is relatively limited. This targeting mechanism allows dasatinib to effectively control the disease while significantly reducing the systemic toxicity associated with traditional chemotherapy when treating Ph+ leukemia.

In addition, dasatinib is often combined with other drugs in clinical use, but its essence is still a molecular targeted therapy. It can overcome imatinib resistance and inhibit resistance problems caused by BCR-ABL domain mutations and SRC family kinase activation. This is also a function that chemotherapy drugs usually cannot achieve. Using TKI drugs, patients usually do not have to experience the severe bone marrow suppression and hair loss and other side effects caused by traditional chemotherapy. At the same time, long-term maintenance treatment can be achieved through oral administration, which is further different from intravenous infusion chemotherapy regimens.

Although dasatinib is not a chemotherapy drug, it still has some serious side effects, such as pleural effusion, abnormal heart rhythm, and bone marrow suppression, which require strict monitoring and dose adjustment. Like chemotherapy drugs, patients should undergo regular blood, liver, kidney and heart function tests under the guidance of a physician during the use of dasatinib to ensure a balance between efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB01254